JINGXIN® Fetal Chromosome Aneuploidy (T21, T18, T13) Testing Kit (Semiconductor Sequencing)
Safe, Fast and Accurate Testing Technique for Noninvasive Fetal Chromosome Aneuploidies
Through analyzing cell-free fetal DNA in maternal peripheral blood plasma, JINGXIN® Fetal Chromosome Aneuploidy (T21, T18, T13) Testing Kit (Semiconductor Sequencing) can accurately detect fetal chromosome aneuploidy diseases (trisomy-21, trisomy-18 and trisomy-13 syndromes). The validation studies using 100,000 clinical samples have been completed. Compared with the analysis results of karyotyping, the accuracy reaches up to 99.9%. The kit has obtained CFDA Medical Device Registration Certificate (Medical Device Registration Certificate No.: National Instrument Registration Permit 0153400300) in Feb. 2015.
Enrichment of Cell-free Fetal DNA
The increase of cell-free fetal DNA concentration (referred to as the fetal concentration) in maternal plasma from the average 13% as reported in the literature to 30% as achieved by our innovative experimental technique greatly improves the accuracy.
Determination of Cell-Free Fetal DNA Concentration
Removal of the maternal genomic DNA interference from maternal plasma samples through the innovative bioinformatics method can allow accurate determination of both male and female fetal concentrations.
More than 100,000 cases of clinical samples have verified that the testing accuracy is above 99.9%.
The kit may not only apply to chromosome aneuploidy testing but also support chromosomal microdeletion/microduplication testing.
Test Kit cung cấp bao gồm:
|Sequenced Sample Size||PI chip: 50~60 samples/time PII chip: 50~60 samples/time|
|Sequencing Times||2~3 times/day|
|Average Sequencing Read Length||>160bp|
|Number of Specific Fragments||4M±20%/sample|
|Reporting Cycle||3 working days|
mọi chi tiết xin vui lòng liên hệ với chúng tôi
ĐẠI DIỆN CAPITALBIO COOPORATION TẠI VIỆT NAM